Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD

The aim of any treatment should be to add life to years and not simply years to life. Surprisingly, the label of erythropoiesis-stimulating agents for anemia treatment in chronic kidney disease does not include the indication for improving quality of life. Merit of the placebo-controlled Anemia Stud...

Full description

Saved in:
Bibliographic Details
Published inKidney international Vol. 103; no. 6; pp. 1025 - 1027
Main Authors Locatelli, Francesco, Del Vecchio, Lucia
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2023
Subjects
Anemia - drug therapy
Anemia - etiology
Goals
Hematinics - therapeutic use
Hemoglobins - analysis
Humans
Quality of Life
Renal Insufficiency, Chronic - therapy
Online AccessGet full text

Cover

More Information
Summary:The aim of any treatment should be to add life to years and not simply years to life. Surprisingly, the label of erythropoiesis-stimulating agents for anemia treatment in chronic kidney disease does not include the indication for improving quality of life. Merit of the placebo-controlled Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) trial was to address this issue by analyzing the effect of anemia treatment with daprodustat aimed at the hemoglobin target range of 11–12 g/dl; the trial demonstrates that partial anemia correction improved quality of life.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:0085-2538
1523-1755
1523-1755
DOI:10.1016/j.kint.2023.03.026